# Commission Regulation (EU) 2015/1221 of 24 July 2015 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress (Text with EEA relevance), Annex

Extent: E+W+S+N.I.

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
(1) Table 3.1 is amended as follows:
(a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:
Index No
International Chemical Identification
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
007-004-00-1
nitric acid … %
231-714-2
7697-37-2
Ox. Liq. 2
Skin Corr. 1A
H272
H314
GHS03
GHS05
Dgr
H272
H314
EUH071
Skin Corr. 1A; H314: C ≥ 20 %
Skin Corr. 1B; H314: 5 % ≤ C < 20 %
Ox. Liq. 2; H272: C ≥ 99 %
Ox. Liq. 3; H272: 99 % > C ≥ 65 %
B
015-003-00-2
calcium phosphide; tricalcium diphosphide
215-142-0
1305-99-3
Water-react. 1
Acute Tox. 2
Acute Tox. 3
Acute Tox. 1
Eye Dam. 1
Aquatic Acute 1
H260
H300
H311
H330
H318
H400
GHS02
GHS06
GHS05
GHS09
Dgr
H260
H300
H311
H330
H318
H400
EUH029
EUH032
M = 100
031-001-00-4
gallium arsenide
215-114-8
1303-00-0
Repr. 1B
Carc. 1B
STOT RE 1
H360F
H350
H372 (respiratory and haematopoietic systems)
GHS08
Dgr
H360F
H350
H372 (respiratory and haematopoietic systems)
050-008-00-3
tributyltin compounds, with the exception of those specified elsewhere in this annex
—
—
Repr. 1B
Acute Tox. 3
Acute Tox. 4*
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H360FD
H301
H312
H372**
H315
H319
H400
H410
GHS08
GHS06
GHS09
Dgr
H360FD
H301
H312
H372**
H315
H319
H410
*
STOT RE 1; H372: C ≥ 1 %
STOT RE 2; H373: 0,25 % ≤ C < 1 %
Skin Irrit. 2; H315:C ≥ 1 %
Eye Irrit. 2; H319:C ≥ 1 %
M = 10
A
1
603-102-00-9
1,2-epoxybutane
203-438-2
106-88-7
Flam. Liq. 2
Carc. 2
Acute Tox. 4*
Acute Tox. 4*
Acute Tox. 4*
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
H225
H351
H302
H312
H332
H335
H315
H319
GHS02
GHS08
GHS07
Dgr
H225
H351
H302
H312
H332
H335
H315
H319
603-197-00-7
tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol
403-640-2
107534-96-3
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H361d***
H302
H400
H410
GHS08
GHS07
GHS09
Wng
H361d***
H302
H410
M = 1
M = 10
606-054-00-7
isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone
—
141112-29-0
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d***
H400
H410
GHS08
GHS09
Wng
H361d***
H410
M = 10
M = 100
607-197-00-8
nonanoic acid
203-931-2
112-05-0
Skin Irrit. 2
Eye Irrit. 2
Aquatic Chronic 3
H315
H319
H412
GHS07
Wng
H315
H319
H412
613-042-00-5
imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
252-615-0
35554-44-0
Carc. 2
Acute Tox. 3
Acute Tox. 4
Eye Dam. 1
Aquatic Chronic 1
H351
H301
H332
H318
H410
GHS08
GHS06
GHS05
GHS09
Dgr
H351
H301
H332
H318
H410
M = 10
613-057-00-7
dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine
216-474-9
1593-77-7
Repr. 2
STOT RE 2
Skin Corr. 1C
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H361d
H373 (liver)
H314
H317
H400
H410
GHS08
GHS05
GHS07
GHS09
Dgr
H361d
H373 (liver)
H314
H317
H410
EUH071
M = 1
M = 1
613-133-00-X
etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole
219-991-8
2593-15-9
Carc. 2
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H302
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H302
H317
H410
M = 1
M = 1
613-149-00-7
pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one
405-700-3
96489-71-3
Acute Tox. 3
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H331
H301
H400
H410
GHS06
GHS09
Dgr
H331
H301
H410
M = 1 000
M = 1 000
(b) the following entries are inserted in accordance with the order of the entries set out in Table 3.1:
Index No
International Chemical Identification
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-factors
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
019-003-00-3
potassium (E,E)-hexa-2,4-dienoate
246-376-1
24634-61-5
Eye Irrit. 2
H319
GSH07
Wng
H319
604-092-00-9
phenol, dodecyl-, branched [1];
phenol, 2-dodecyl-, branched;
phenol, 3-dodecyl-, branched;
phenol, 4-dodecyl-, branched;
phenol, (tetrapropenyl) derivatives [2]
310-154-3 [1]
121158-58-5 [1]
74499-35-7 [2]
Skin Corr. 1C
Aquatic Acute 1
Aquatic Chronic 1
H314
H400
H410
GHS05
GHS09
Dgr
H314
H410
M = 10
M = 10
606-148-00-8
carvone (ISO);
2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]
d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]
l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]
202-759-5 [1]
218-827-2 [2]
229-352-5 [3]
99-49-0 [1]
2244-16-8 [2]
6485-40-1 [3]
Skin Sens. 1
H317
GHS07
Wng
H317
606-149-00-3
tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione
—
335104-84-2
Repr. 2
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H361d
H373 (eyes, kidneys, liver)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361d
H373 (eyes, kidneys, liver)
H317
H410
M = 100
M = 10
607-707-00-9
fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate
—
71283-80-2
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373 (kidneys)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373 (kidneys)
H317
H410
M = 1
M = 1
607-708-00-4
octanoic acid
204-677-5
124-07-2
Skin Corr. 1C
Aquatic Chronic 3
H314
H412
GHS05
Dgr
H314
H412
607-709-00-X
decanoic acid
206-376-4
334-48-5
Skin Irrit. 2
Eye Irrit. 2
Aquatic Chronic 3
H315
H319
H412
GHS07
Wng
H315
H319
H412
607-710-00-5
1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear
271-093-5
68515-50-4
Repr. 1B
H360FD
GHS08
Dgr
H360FD
607-711-00-0
spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate
—
203313-25-1
Repr. 2
STOT SE 3
Eye Irrit. 2
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
H361fd
H335
H319
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H361fd
H335
H319
H317
H410
M = 1
M = 1
607-712-00-6
dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate
250-778-2
31717-87-0
Repr. 2
STOT RE 2
Skin Corr. 1C
Skin Sens. 1A
Aquatic Chronic 1
H361d
H373 (liver)
H314
H317
H410
GHS08
GHS05
GHS07
GHS09
Dgr
H361d
H373 (liver)
H314
H317
H410
EUH071
M = 1
607-713-00-1
fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate
—
134098-61-6
Acute Tox. 3
Acute Tox. 2
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H301
H330
H317
H400
H410
GHS06 GHS09
Dgr
H301
H330
H317
H410
M = 100
M = 1 000
607-714-00-7
triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate
—
126535-15-7
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 100
M = 10
607-715-00-2
bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate
442-820-5
149877-41-8
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373
H317
H410
M = 1
M = 1
613-319-00-0
imidazole
206-019-2
288-32-4
Repr. 1B
Acute Tox. 4
Skin Corr. 1C
H360D
H302
H314
GHS08
GHS07
GHS05
Dgr
H360D
H302
H314
613-320-00-6
lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione
218-499-0
2164-08-1
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H400
H410
GHS08
GHS09
Wng
H351
H410
M = 10
M = 10
616-213-00-2
mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide
—
374726-62-2
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 1
M = 1
616-214-00-8
metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide
—
139528-85-1
Carc. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H373 (eyes, kidneys)
H400
H410
GHS08
GHS09
Wng
H351
H373 (eyes, kidneys)
H410
M = 1 000
M = 100
616-215-00-3
dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide
—
163515-14-8
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H317
H400
H410
GHS07
GHS09
Wng
H302
H317
H410
M = 10
M = 10
616-216-00-9
flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide
—
158062-67-0
Acute Tox. 4
H302
GHS07
Wng
H302
616-217-00-4
sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide
—
946578-00-3
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
M = 1
M = 1
(2) Table 3.2 is amended as follows:
(a) the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:
Index No
International Chemical Identification
EC No
CAS No
Classification
Labelling
Concentration Limits
Notes
007-004-00-1
nitric acid … %
231-714-2
7697-37-2
O; R8
C; R35
O; C
R: 8-35
S: (1/2-)26-28- 36/37/39-45-63
O; R8: C ≥ 65 %
C; R35: C ≥ 20 %
C; R34: 5 % ≤ C < 20 %
B
015-003-00-2
calcium phosphide; tricalcium diphosphide
215-142-0
1305-99-3
F; R15/29
T+; R26/28
Xn; R21
R32
Xi; R38-41
N; R50
F; T+; N
R: 15/29-21-26/28-32-38-41-50
S:(1/2-)26-28-30-36/37/39-43-45-60-61
N; R50: C ≥ 0,25 %
031-001-00-4
gallium arsenide
215-114-8
1303-00-0
Repr. Cat. 2; R60
Carc. Cat. 2; R45
T; R48/23
T
R: 45-48/23-60
S: 45-53
E
050-008-00-3
tributyltin compounds, with the exception of those specified elsewhere in this annex
—
—
Repr. Cat. 2; R60-61
T; R25-48/23/25
Xn; R21
Xi; R36/38
N; R50-53
T; N
R: 21-25-36/38-48/23/25-50/53-60-61
S: 45-53-60-61
T; R25: C ≥ 2,5 %
Xn; R22: 0,25 % ≤ C < 2,5 %
Xn: R21: C ≥ 1 %
T; R48/23/25: C ≥ 1 %
Xn; R48/20/22: 0,25 % ≤ C < 1 %
Xi; R36/38: C ≥ 1 %
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
A
1
603-102-00-9
1,2-epoxybutane
203-438-2
106-88-7
F; R11
Carc. Cat. 3; R40
Xn; R20/21/22
Xi; R36/37/38
F; Xn
R: 11-20/21/22-36/37/38-40-
S: (2-)9-16-29-36/37-46
603-197-00-7
tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol
403-640-2
107534-96-3
Repr. Cat. 3; R63
Xn; R22
N; R50-53
Xn; N
R: 22-50/53-63
S: (2-)22-36/37-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C <25 %
R52-53: 0,25 % ≤ C < 2,5 %
606-054-00-7
isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone
—
141112-29-0
Repr. Cat. 3; R63
N; R50-53
Xn; N
R: 50/53-63
S: (2-)36/37-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
607-197-00-8
nonanoic acid
203-931-2
112-05-0
Xi; R36/38
N; R51-53
Xi; N
R: 36/38-51/53
S: (2-)46-61
613-042-00-5
imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
252-615-0
35554-44-0
Carc. Cat. 3; R40
Xn; R20/22
Xi; R41
N; R51-53
Xn; N
R: 20/22-40-41-51/53
S: (2-)26-36/37/39-46-61
613-057-00-7
dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine
216-474-9
1593-77-7
Repr. Cat. 3; R63
C; R34
R43
N; R50-53
C; N
R: 34-43-50/53-63
S: (1/2-)26-28-36/37/39-45-60-61
C; R34: C ≥ 10 %
Xi; R36/37/38: 5 % ≤ C < 10 %
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-133-00-X
etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole
219-991-8
2593-15-9
Carc. Cat. 3; R40
Xn; R22
R43
N; R50-53
Xn; N
R: 22-40-43-50/53
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-149-00-7
pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one
405-700-3
96489-71-3
T; R23/25
N; R50-53
T; N
R: 23/25-50/53
S: (1/2-)36/37-45-60-61
N; R50-53: C ≥ 0,025 %
N; R51-53: 0,0025 % ≤ C < 0,025 %
R52-53: 0,00025 % ≤ C < 0,0025 %
(b) the following entries are inserted in accordance with the order of the entries set out in Table 3.2:
Index No
International Chemical Identification
EC No
CAS No
Classification
Labelling
Concentration Limits
Notes
019-003-00-3
potassium (E,E)-hexa-2,4-dienoate
246-376-1
24634-61-5
Xi; R36
Xi
R: 36
S: (2-)25-46
604-092-00-9
phenol, dodecyl-, branched [1];
phenol, 2-dodecyl-, branched;
phenol, 3-dodecyl-, branched;
phenol, 4-dodecyl-, branched;
phenol, (tetrapropenyl) derivatives [2]
310-154-3 [1]-[2]
121158-58-5 [1]
74499-35-7 [2]
C; R34
N; R50-53
C; N
R: 34-50/53
S: (1/2-)26-36/37/39-45-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
606-148-00-8
carvone (ISO);
2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]
d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]
l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]
202-759-5 [1]
218-827-2 [2]
229-352-5 [3]
99-49-0 [1]
2244-16-8 [2]
6485-40-1 [3]
R43
Xi
R: 43
S: (2-)24-37
606-149-00-3
tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione
335104-84-2
Repr. Cat. 3; R63
Xn; R48/22
R43
N; R50-53
Xn; N
R: 43-48/22-50/53-63
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
607-707-00-9
fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate
—
71283-80-2
Xn; R48/22
R43
N; R50-53
Xn; N
R: 43-48/22-50/53
S: (2-)24-37-46-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
607-708-00-4
octanoic acid
204-677-5
124-07-2
C; R34
N; R51-53
C; N
R: 34-51/53
S: (1/2-)26-36/37/39-45-61
607-709-00-X
decanoic acid
206-376-4
334-48-5
Xi; R36/38
N; R51-53
Xi; N
R: 36/38-51/53
S: (2-)25-46-61
607-710-00-5
1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear
271-093-5
68515-50-4
Repr. Cat. 2; R60-61
T
R: 60-61
S: 53-45
607-711-00-0
spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate
—
203313-25-1
Repr. Cat. 3; R62-63
Xi; R36/37
R43
N; R50-53
Xn; N
R: 36/37-43-50/53-62-63
S: (2-)36/37-60-61
Xi; R43: C ≥ 0,1 %
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
607-712-00-6
dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate
250-778-2
31717-87-0
Repr. Cat. 3; R63
C; R34
R43
N; R51-53
C; N
R: 34-43-51/53-63
S: (1/2-)26-28-36/37/39-45-61
C; R34: C ≥ 10 %
Xi: R36/37/38: 5 % ≤ C < 10 %
607-713-00-1
fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate
—
134098-61-6
T+; R26
Xn; R22
R43
N; R50-53
T+; N
R: 22-26-43-50/53
S: (1/2-)28-36/37-45-60-61-63
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
607-714-00-7
triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate
—
126535-15-7
Carc. Cat. 3; R40
N; R50-53
Xn; N
R: 40-50/53
S: (2-)36/37-60-61
N; R50-53: C ≥ 0,25 %
N; R51-53: 0,025 % ≤ C < 0,25 %
R52-53: 0,0025 % ≤ C < 0,025 %
607-715-00-2
bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate
442-820-5
149877-41-8
R43
N; R50-53
Xi; N
R: 43-50/53
S: (2-)24-37-60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %
613-319-00-0
imidazole
206-019-2
288-32-4
Repr. Cat 2; R61
Xn; R22
C; R34
T; C
R: 22-34-61
S: 53-45
613-320-00-6
lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione
218-499-0
2164-08-1
Carc. Cat. 3; R40
N; R50-53
Xn; N
R: 40-50/53
S: (2-)36/37-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
616-213-00-2
mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide
—
374726-62-2
N; R50-53
N
R: 50/53
S: 60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C <25 %
R52-53: 0,25 % ≤ C < 2,5 %
616-214-00-8
metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide
—
139528-85-1
Carc. Cat. 3; R40
Xn; R48/22
N; R50-53
Xn; N
R: 40-48/22-50/53
S: (2-)36/37-46-60-61
N; R50-53: C ≥ 0,025 %
N; R51-53: 0,0025 % ≤ C < 0,025 %
R52/53: 0,00025 % ≤ C < 0,0025 %
616-215-00-3
dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide
—
163515-14-8
Xn; R22
R43
N; R50-53
Xn; N
R: 22-43-50/53
S: (2-)24-37-60-61
N; R50-53: C ≥ 2,5 %
N; R51-53: 0,25 % ≤ C < 2,5 %
R52-53: 0,025 % ≤ C < 0,25 %
616-216-00-9
flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide
—
158062-67-0
Xn; R22
Xn
R: 22
S: (2-)46
616-217-00-4
sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide
—
946578-00-3
Xn; R22
N; R50-53
Xn; N
R: 22-50/53
S: (2-)60-61
N; R50-53: C ≥ 25 %
N; R51-53: 2,5 % ≤ C < 25 %
R52-53: 0,25 % ≤ C < 2,5 %

---
Source: https://www.legislation.gov.uk/eur/2015/1221/annex (the official version)
Page: https://openlegislation.uk/eu-regulation-2015-1221/annex
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.